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Various methods are available to formulate water soluble
drugs into sustained release dosage forms by retarding
the dissolution rate. One of the methods used to control
drug release and thereby prolong therapeutic activity is
to use hydrophilic and lipophilic polymers. In this study,
the effects of various polymers such as hydroxypropyl
methylcellulose (HPMC), ethylcellulose (EC) and so-
dium carboxymethylcellulose (CMC) and surfactants
(sodium lauryl sulphate, cetyltrimethylammonium bro-
mide and Arlacel 60) on the release rate of captopril we-
re investigated. The results showed that an increase in
the amount of HPMC K15M resulted in reduction of the
release rate of captopril from these matrices. When
HPMC was partly replaced by NaCMC (the ratio of
HPMC/NaCMC was 5:1), the release rate of the drug
significantly decreased. However, there was no signifi-
cant difference in release rate of captopril from matrices
produced with ratios of 5:1 and 2:1 of HPMC/NaCMC.
The presence of lactose in matrices containing HPMC
and NaCMC increased the release rate of captopril. It
was interesting to note that although partial replacement
of HPMC by EC reduced the release rate of the drug (ra-
tio of HPMC/EC 2:1), the release rate was increased
when the ratio of HPMC/EC was reduced to 1:1. The ef-
fects of various surfactants on the release rate of captop-
ril from HPMC/EC (1:1) matrices were also investigated.
The results showed that the surfactants did not signifi-
cantly change the release rate of the drug. Release data
were examined kinetically and the ideal kinetic models
were estimated for the drug release. The kinetic analysis
of drug release data from various formulations showed
that incorporation of surfactants in HPMC/EC matrices
did not produce a zero-order release pattern.
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Captopril is freely water-soluble and has an elimination half-life of 1.7 h after an
oral dose (1). It is usually prescribed to patients who are chronically ill and require long-
-term use for therapeutic benefit. Development of a once daily captopril oral formulation
would be a significant advantage for patient compliance accompanied by minimization
of the drug side effects as a result of reduction in the drug blood concentration fluctua-
tions, especially in long-term therapy (2).
The release of highly water-soluble medicinal compounds having fast rates of disso-
lution is of special interest. Matrix tablets have long been used to obtain sustained drug
delivery and it was Higuchi (3) who first presented a detailed mathematical analysis of
such release. Bomba et al. (4) further developed the mechanisms of release from matrix
systems that swell at the tablet periphery to form a gel which acts as a barrier to drug
diffusion.
Various studies of the release from matrices in which a surfactant had been incorpo-
rated showed a faster release with the addition of surfactant (5, 6). According to the im-
portance of captopril sustained release formulation in clinical use, different attempts have
been made to design long acting devices for captopril delivery in the form of sustained
or controlled release formulations (7–9). The effect of surfactants was not studied in con-
trolled or sustained-release formulations for captopril delivery. Therefore, the present
study firstly concerns the release of captopril from hydroxypropylmethylcellulose
(HPMC K15M), sodium carboxymethylcellulose (NaCMC), ethylcellulose (EC) and their
mixtures matrices and secondly the effect of anionic, cationic, and nonionic surfactants
incorporated in an inert, heterogeneous HPMC matrix in order to obtain zero-order re-
lease formulations. This study also examines the effect of surfactants on the mechanism
of drug release from HPMC-EC matrices.
EXPERIMENTAL
Materials
Captopril (Iran Darou, Iran), Methocel K15M (Colorcon, UK), NaCMC (Aqualon,
France), ethylcellulose (Merck, Germany), lactose (BDH Chemicals, UK), magnesium
stearate (BDH Chemicals), Tween 80 (Merck), Arlacel 60 (BDH Chemicals), sodium
lauryl sulphate SLS (BDH Chemicals) and cetytrimethyl ammonium bromide (CTAB)
(Merck) were used as obtained.
Preparation of tablets
Captopril matrices were produced by mixing captopril with HPMC K15M, ethylcel-
lulose, NaCMC or their mixture for a period of 15 min in a double cone mixer. After
completed mixing, magnesium stearate was added and mixed for 2 min. The mixtures
were compressed on a 9-mm punch at a pressure of 150 MPa (Table I).
In case of formulations F8 and F9, 25% and 50% of HPMC was mixed with drug-lac-
tose (ratio 1:1), respectively, and granulated with distilled water. The moist granules we-
re passed through a sieve (aperture size 1.4 mm). The granules were dried in an oven at
60 °C for a period of 24 h. The dried granules were mixed with the remainder of HPMC
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and NaCMC for 10 min. After completed mixing, magnesium stearate was added and
mixed for 2 min. The mixtures were compressed on a 9-mm punch at a pressure of 150
MPa (Table I).
A mixture of HPMC and ethylcellulose (1:1) was chosen to investigate the effect of
surfactant on the release rate of captopril from matrices (see Table I). Captopril (25 g)
was mixed well with the mixture of HPMC (75 g) and ethylcellulose (75 g) for a period
of 15 min in a double cone mixer. Then the mixture was transferred to mortar with pes-
tle and surfactant was added (3, 6 or 12%, m/m) to the mixture and mixed for an additio-
nal period of 15–20 min. After completed mixing, magnesium stearate was added and
mixed for 2 min. The mixtures were compressed on a 9-mm punch at a pressure of 150
MPa (Table I). The amount of captopril was 50 mg in all formulations.
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Table I. Different formulations of captopril matrices and their compositions
Code
Lactose
(mg)
HPMC
(mg)
NaCMC
(mg)
EC
(mg)
CTAB
(mg)
Arlacel 60
(mg)
SLS
(mg)
F1 – 50 – – – – –
F2 – 100 – – – – –
F3 – 150 – – – – –
F4 – 125 25 – – – –
F5 – 100 50 – – – –
F6 25 100 25 – – – –
F7b 50 75 25 – – – –
F8c 50 75 25 – – – –
F9d 50 75 25 – – – –
F10 – 100 – 50 – – –
F11 – 75 – 75 – – –
F12 – 75 – 75 – – 4.5 (3%)
F13 – 75 – 75 – – 9.5 (6%)
F14 – 75 – 75 – – 20.5 (12%)
F15 – 75 – 75 4.5 (3%) – –
F16 – 75 – 75 9.5 (6%) – –
F17 – 75 – 75 20.5 (12%) – –
F18 – 75 – 75 – 4.5 (3%) –
F19 – 75 – 75 – 9.5 (6%) –
F20 – 75 – 75 – 20.5 (12%) –
a Amount of captopril in all formulation is 50 mg.
b Simple mixture.
c 25% of HPMC was granulated with water.
d 50% of HPMC was granulated with water.
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Dissolution studies
The USP basket method (10) was used for all in vitro dissolution studies. In this met-
hod, distilled water containing HCl 0.1 mol L–1, which simulated gastric fluid (pH 1.2),
and intestinal fluid (pH 6.8) containing phosphate buffer without enzyme were used as
dissolution media. Phosphate buffer was prepared according to USP (10) from of 0.2 mol L–1
monobasic potassium phosphate and 0.2 mol L–1 sodium hydroxide. The stirring rate
was 100  2 rpm. Matrices were placed in 900 mL of gastric fluid and maintained at 37 
0.1 °C for 2 h. At appropriate intervals, 5 mL of samples were taken and filtered through
a 0.45-m Millipore filter. The dissolution medium was then replaced by 5 mL of fresh
dissolution fluid to maintain a constant volume. After 2 hours, the dissolution medium
pH was changed from 1.2 to 6.8 using phosphate buffer to simulate intestinal fluid. The
samples were then analyzed at 205 and 206 nm at pH 1.2 and 6.8, respectively, using a
UV/Vis spectrophotometer (Shimadzu, Japan) (10). The mean of three determinations
was used to calculate the drug release from each formulation.
Release parameters
To investigate the mode of drug release from matrices, Eq. (1) was applied to inter-
pret the release rate from matrices (11):
Q = K1tn (1)
where Q is the percent of drug released at time t, K1 is the constant incorporating struc-
tural and geometric characteristics of the release device and n is the release exponent in-
dicative of the mechanism of release. When n approximates 0.5, a Fickian/diffusion-con-
trolled release is implied, where 0.5 < n < 1.0 non-Fickian transport and n = 1 for zero-
-order (case II transport). When the value of n approaches 1.0, one may phenomenologi-
cally conclude that the release is approaching zero-order.
To compare the effects of polymer or surfactant type or concentration on the drug
release, different criteria were used, such as mean dissolution time (MDT) and dissolu-
tion efficiency (DE). Mean dissolution time is described below (12):
MDT
t Mj
tMj
j
n
j
n=
=
=
∑
∑
∆
1
1
(2)
where j is the sample number, n is the number of dissolution times, t is the time at mid-
point between t and t–1 (easily calculated with (t + t–1)/2) and Mj is the additional
amount of drug dissolved between t and t–1. Dissolution efficiency (DE) was used as the
criterion for comparing the effect of polymer and surfactant concentration on the release
rate. The dissolution efficiency (DE) of a pharmaceutical dosage form is defined as the
area under the dissolution curve up to a certain time, t, expressed as percentage of the
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area of the rectangle described by 100% dissolution in the same time. DE is described be-
low (13):
DE
Y dt
Y T
T
=
×
×
×
∫
0
100
100% (3)
where Y is the percent drug release as the function of time, t, T is the total time of drug
release and Y100 is 100% drug release.
Statistical analysis
All data were statistically analyzed by the analysis of variance or Tukey’s multiple
comparison test.
RESULTS AND DISCUSSION
All formulations were relatively robust in terms of friability and hardness (Table II). Ta-
ble I shows the formulation compositions analyzed in this study. The effect of HPMC
K15M concentration on the release rate of captopril is shown in Fig. 1a. The results
showed that an increase in the concentration of HPMC (F1–F3) resulted in a reduction of
the captopril release rate. DE and MDT were used to compare the dissolution data. The
results of fitting the dissolution data with these dissolution criteria are shown in Table II.
DE values are consistent with the dissolution data. For example, the DE value for the
tablets containing 50 mg HPMC is 72.7% whereas this value decreased to 62.2 or 50% for
the tablets containing 100 or 150 mg HPMC, respectively. The ANOVA statistical test
showed that the reduction in DE percentage was significant (p < 0.05). However, it seems
that the amount of HPMC does not change the release pattern. No positive deviation oc-
curred from the curves, indicating that attrition did not contribute to drug release (14).
Simple examination of Fig. 1a shows that as the polymer fraction increased, the dis-
solution of the drug decreased. However, a prospective formulator would require a mo-
re quantitative rationalisation of these trends. The slopes (% min–1/2) of Eq. (1) are given
in Table II. When these slopes were plotted as a function of the reciprocal of the HPMC
concentration at which they were obtained, a straight line plot was obtained (correlation
coefficient 0.999). The general relationship for the line can be expressed by Eq. (4).
R = M (1/W) + C (4)
where R is the Higuchian release rate (% min–1/2), M is the slope of derived line (%
min–1/2 mg), W is the mass of HPMC (mg), C is the constant (% min–1/2) representing
the captopril release rate at a theoretically infinitely high HPMC level.
The derived values of M and C were 756 and 0.364, respectively. The data mentio-
ned above permit the dissolution rate to be estimated from a limited number of data
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points. Such a relationship was also obtained for promethazine hydrochloride with va-
rying concentrations of HPMC of different viscosity grade (15).
Fig. 1b shows the effect of incorporated NaCMC on the release rate of captopril
from HPMC matrices. The results indicate that replacement of HPMC with NaCMC cau-
sed a considerable reduction (p < 0.05) in drug release (compare release profiles of F3
and F4 in Fig. 1b and also DE and MDT in Table II). DE and MDT values significantly
changed from 40% and 178.9 min to 53% and 144.6 min for F4 and F6 formulations, res-
pectively. However, there was no significant difference between formulations F4 the
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Fig. 1. The effect of various polymers, lactose
and granulation technique on the release of
captopril from polymeric matrices: a) HPMC
K15M; b) NaCMC; c) lactose; d) granulated
HPMC; e) ethylcellulose (results are the mean
 standard deviation of at least 3 runs).
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(HPMC/NaCMC ratio was 5:1) and F5 (the HPMC/NaCMC ratio was 2:1). For example,
after 4 h, the amounts of drug released from formulations F3, F4 and F5 were 50, 42 and
43%, respectively.
Fig. 1c shows the dissolution characteristics of matrices prepared with different ra-
tios of HPMC/lactose. Addition of lactose led to a significant increase (p < 0.05) in the
release rate of captopril (compare F4 and F6 in Fig. 1c). An increase in the amount of lac-
tose from 25 (formulation F6) to 50 mg (formulation F7) resulted in an increase in the re-
lease rate of captopril (Fig. 1c). For example, after 4 h, the percentages of drug released
were 42, 57 and 61% from matrices containing 0, 25 and 50 mg lactose, respectively. This
could be due to a reduction in the tortuosity of the diffusion path of the drug caused by
lactose and/or the gel layer became thinner because of smaller amount of HPMC in the-
se formulations. It was interesting to note that the granulating of HPMC with water had
a significant effect on drug release. For instance in Fig. 1d, F7 was a simple mixture of
components, in F8 and F9, 25 and 50% of HPMC was granulated with water and then
mixed with other ingredients. The figure shows that when 25% of granulated HPMC
was incorporated into the matrix formulation, the amount of drug released increased
from 61 to 84% after 4 h (compare F7 and F8). As more granulated HPMC was incorpo-
rated, there was no significant increase in the release rate of captopril.
Fig. 1e shows the effect of ethylcellulose on the release rate of captopril from HPMC
matrices. Although partial replacement of HPMC by EC increased the release rate of the
drug (F3 and F11 in Fig. 1e), when the ratio of HPMC/EC was reduced to 1:1 (F11), the
amount of captopril released increased from 52 to 62%. It can be seen that the difference
in release profiles of F3, F10 and F11 is more significant at pH 6.8 than it is at pH 1.2.
To investigate the effects of surfactants on the release rate of captopril, HPMC
K15M/EC (1:1) was chosen as the inert matrix. The release of captopril from matrices
containing different percentages of SLS (formulations F11–F14) was measured. The re-
lease rate of captopril from Methocel K15M-EC matrices was generally decreased by the
anionic surfactant (Fig. 2a). The rate of drug release slightly decreased as more surfac-
tant was added to the formulation. ANOVA and Tukey’s multiple comparison tests
showed that the presence of SLS did not cause any significant changes in the amount of
drug released from these matrices, with the exception of high SLS concentration (12%).
The presence of high SLS concentration (12%) caused a significant decrease in drug re-
lease (p < 0.05). For instance, the amount of captopril released decreased from 65 to 55%
after 4 h.
As captopril has two pKas 3.7 (weak acid) and 9.8 (very weak acid), the drug will be
in cationic form (about 99%) at pH 1.2 possessing the ability of complex formation with
the anionic surfactant SLS. Thus SLS is expected to retard the release rate of captopril at
pH 1.2. The data showed that SLS retarded the release of captopril at pH 6.8. At higher
SLS concentration (12%), the release rate of captopril was higher than in SLS 6%, m/m. At
pH 6.8, captopril has a negative charge on the carboxyl group and a positive charge on
nitrogen. Therefore, SLS is still able to interact with the cationic group to make a com-
plex. In addition, the retardation effect of SLS could be due to enhanced viscosity of the
gel layer surrounding the matrix, which leads to reduction in the release rate of drugs
(16). Walderhasug et al. (17) studied the nature of the interaction between SLS and cellu-
lose ethers. They concluded that the anionic surfactant could bind to the non-ionic cellu-
lose to form a strong gel network. Furthermore, complexation and subsequent precipita-
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tion provide a more tortuous pathway and less porous matrix through which the
dissolved medicinal compound must diffuse (18). Daly et al. (19) found that the incorpo-
ration of 15% SLS in modified hydroxypropyl methylcellulose matrices produced a zero-
-order release of chlorpheniramine maleate. Feely and Davis (20) reported that the relea-
se rate of chlorpheniramine maleate from a HPMC matrix was reduced as more SLS was
incorporated into the matrix.
The release of captopril from matrices containing CTAB as cationic surfactant 0–12%
(m/m) (formulations F3, F13–F15) is shown in Fig. 2b. The release of the drug from the
matrices was increased by the cationic surfactant CTAB at pH 1.2. As the concentration
of CTAB increased from 0 to 12% (m/m), the amount of the drug released increased from
38 to 45% after 2 hours. As captopril has a positive charge at pH 1.2, CTAB is not able to
interact with captopril.
The release of captopril from matrices containing 0–12% m/m Arlacel 60 as non-ionic
surfactant (formulations F11, F18–F20) is illustrated in Fig. 2c. It can be seen that the re-
lease rate was not affected significantly as the concentration of Arlacel 60 was increased
from 0 to 12%. Similar results were obtained when DE and MDT were compared for ma-
trices with different concentrations of Arlacel. The results (Table II) showed that the pre-
sence of Arlacel in concentrations of 3–12% had no significant effect on DE and MDT.
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Fig. 2. The effect of different concentrations of
various surfactants on the release rate of cap-
topril from polymeric matrices: a) SLS; b)
CTAB; c) Arlacel (results are the mean  stan-
dard deviation of 3 determinations).
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It can be concluded for these surfactants that wetting does not play a significant role
in the dissolution process and that the minor acceleration or retardation observed with
the incorporation of CTAB and SLS might be due to the surfactant dissolving and form-
ing pores/channels, which increases the effective surface area by a method other than
wetting.
Two possible mechanisms have been postulated as to why surfactants increase the
rate of drug release from matrix formulations (21, 22). Firstly, it is possible that the sur-
factant lowers the interfacial tension between the product and the dissolution fluid; sec-
ondly, it is possible that the surfactant acts as a wicking agent, causing the fluid to enter
the dosage form; the surfactant may then dissolve and form pores (or other disruptions)
from which the drug release may be affected (21). The same results were reported on the
effect of surfactants on the dissolution profiles of flurbiprofen (22). Efentakis et al. (18)
showed that in most cases, wetting plays a small role in aiding dissolution. They conclu-
ded that the major mechanism by which surfactants increase the dissolution rate is the
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Table II. Hardness, K1, n and R based on Eq. (1) for controlled release formulations of captopril
Formulation
code
Hardness
(kg)
K1 n R DE (%)a MDT (min)a
F1 10  2 9.50 0.38 0.966 72.7  5.2 84.2  9.8
F2 12  2 5.38 0.46 0.994 62.2  2.4 120.2  12.1
F3 11  3 3.14 0.52 0.988 50.0  2.1 133.5  11.9
F4 9  2 0.41 0.85 0.985 40.1  2.4 178.9  13.5
F5 11  2 0.49 0.82 0.983 41.6  2.5 172.2  12.3
F6 10  3 3.65 0.50 0.994 53.0  3.5 144.6  13.4
F7 12  3 4.17 0.49 0.988 56.9  4.2 141.8  8.6
F8 14  2 3.83 0.56 0.995 73.0  5.2 115.3  12.0
F9 15  3 4.07 0.54 0.997 69.7  4.0 116.6  8.9
F10 9  1 1.69 0.62 0.983 52.1  2.1 163.2  14.2
F11 11  2 2.27 0.59 0.993 55.5  2.9 145.1  11.2
F12 12  1 2.91 0.55 0.994 54.9  4.0 142.9  10.8
F13 13  2 2.38 0.57 0.997 50.3  2.9 141.0  10.6
F14 9  2 1.46 0.66 0.993 50.4  3.5 150.5  11.0
F15 11  1 2.13 0.60 0.991 55.2  2.1 138.5  11.3
F16 12  2 3.30 0.53 0.995 57.5  1.9 131.7  8.9
F17 11  2 4.90 0.46 0.998 59.1  3.5 122.6  8.7
F18 9  3 3.11 0.53 0.998 54.6  2.9 145.4  11.2
F19 9  3 2.96 0.55 0.995 56.9  3.1 140.8  11.9
F20 10  2 2.21 0.59 0.998 53.0  2.6 144.0  9.9
a Mean  SD, n = 3.
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formation of pores to aid the access of the dissolution fluid and egress of the dissolved
drug. It is also possible that the presence of the relatively concentrated surfactant solu-
tion in the wetted tablet would reduce interparticle adhesion and thereby enhance the
drug release rate as a result of increased disintegration.
As captopril is a highly soluble drug, the release will be predominantly controlled
by diffusion. The release kinetics from matrices composed of varying ratios of poly-
mer(s) and surfactants were analyzed using Eq. (1); the results are shown in Table II. It
can be observed that increasing HPMC concentration leads to higher n values. It is clear-
ly seen that the n values for matrices containing HPMC or the mixtures of HPMC and
lactose are around 0.5 because of the high solubility of captopril in dissolution media,
indicating the diffusion release mechanism. Table II shows that incorporating NaCMC in
HPMC matrices leads to a significant increase in n values. This indicates that the presen-
ce of NaCMC in HPMC matrices increases the contribution of erosion in the captopril re-
lease.
The presence of higher concentration (12%, m/m) of the anionic surfactant (SLS)
slightly increased the n value. The values of n were between 0.55 and 0.66 for matrices
containing different concentrations of SLS, ranging from 0–12% (m/m). In other words,
there is a slightly higher contribution of diffusion in the presence of 3 or 6% SLS compa-
red to with the matrices with 12% surfactant. A similar result was obtained for matrices
containing Arlacel 60, in which the contribution of diffusion was predominant at lower
concentration of surfactants (3 and 6%, m/m). Table II also shows that an increase in the
concentration of CTAB results in a reduction in the value of n. For example, when the
concentration of CTAB is increased from 3 to 6 and 12% (m/m), the value of n was redu-
ced from 0.60 to 0.53 and 0.46, respectively. This shows that a low concentration of CTAB
has no significant effect on the mechanism of release, whereas the contribution of diffu-
sion increases with higher CTAB concentrations compared to with matrices without the
surfactant (F11).
CONCLUSIONS
The present work has showed that surfactants can be used to control the release rate
of captopril from HPMC-EC matrices. However, they are not able to produce the
zero-order release pattern for captopril matrices. The magnitude of the increase or dec-
rease of release rate remarkably depends on the type of surfactant and on concentration.
The results also show that the surfactants are able to change the mechanism of captopril
release from the matrices. The principal mechanism by which surfactants retard drug re-
lease from HPMC-EC matrices is the drug/surfactant ionic interaction.
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S A @ E T A K
Utjecaj razli~itih povr{inski aktivnih tvari i njihovih koncentracija
na kontrolirano osloba|anje kaptoprila iz polimernih matriksa
ALI NOKHODCHI, DAVOUD HASSAN-ZADEH, FARNAZ MONAJJEM-ZADEH i NITA TAGHI-ZADEH
Postoje razli~ite metode formuliranja vodotopljivih lijekova u dozirane ljekovite
oblike s polaganim osloba|anjem. Jedan od na~ina postizanja kontroliranog otpu{tanja,
a prema tome i produljenog u~inka je upotreba hidrofilnih i lipofilnih polimera. U ovom
radu prou~avan je utjecaj razli~itih polimera poput hidroksipropil metilceluloze (HPMC),
etilceluloze (EC) i natrijeve soli karboksimetilceluloze (NaCMC) i povr{inski aktivnih
tvari (natrijevog lauril-sulfata, cetiltrimetilamonijevog bromida i Arlacela 60) na osloba-
|anje kaptoprila. Rezultati pokazuju da pove}anje koli~ine HPMC K15M ima za poslje-
dicu smanjenje osloba|anja kaptoprila iz matriksa. Ako se HPMC djelomi~no zamijeni s
NaCMC (omjer HPMC/NaCMC 5:1), osloba|anje ljekovite tvari zna~ajno se smanjuje.
Me|utim, nema zna~ajne razlike u osloba|anju kaptoprila iz matriksa s omjerom HPMC/
NaCMC 5:1 i 2:1. Prisutnost laktoze u matriksu koji sadr`i HPMC i NaCMC pove}alo je
osloba|anje kaptoprila. Iako djelomi~na zamjena HPMC s EC smanjuje osloba|anje lje-
kovite tvari (omjer HPMC/EC 2:1), osloba|anje se pove}ava uz omjer HPMC/EC 1:1.
Nadalje, ispitivan je utjecaj povr{inski aktivnih tvari na osloba|anje kaptoprila iz mat-
riksa u kojima je omjer HPMC/EC (1:1). Mo`e se zaklju~iti da povr{inski aktivne tvari
ne utje~u zna~ajno na osloba|anje ljekovite tvari. U sklopu istra`ivanja odre|en je i ki-
neti~ki model osloba|anja kaptoprila. Analiza kineti~kih podataka ukazuje da dodatak
povr{inski aktivnih tvari u HPMC/EC matrikse ne slijedi kinetiku nultog reda.
Klju~ne rije~i: kaptopril, polimeri, kontrolirano osloba|anje, povr{inski aktivna tvar, kinetika oslo-
ba|anja
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